<DOC>
	<DOCNO>NCT01555099</DOCNO>
	<brief_summary>The purpose study assess efficacy safety two stagger dose level inhale daily AZD5423 twice daily budesonide 12 week COPD patient background therapy formoterol .</brief_summary>
	<brief_title>Multi-centre Study Assess Efficacy Safety AZD5423 COPD Patients Background Therapy Formoterol</brief_title>
	<detailed_description>A phase-II , double-blind , placebo-controlled , randomised , parallel-group , multi-centre study ass efficacy safety two stagger dose level inhale daily AZD5423 twice daily budesonide 12 week COPD patient background therapy formoterol .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Provision sign date informed consent prior conduct study specific procedure Men woman age ≥ 40 year Men postmenopausal surgically sterile woman . Women consider postmenopausal amenorrheic least 12 month , follicle stimulate hormone ( FSH ) plasma concentration within postmenopausal range define laboratory . Male patient willing use barrier contraception , i.e . condom ( spermicide ) day dose least 5 week last dose study drug . Clinical diagnosis COPD 1 year Visit 1 , accord GOLD guideline Current maintenance therapy LABA and/or LAMA , ICS/LABA ICS plus LAMA combination Current exsmokers smoke history equivalent least 10 pack year ( 1 pack year = 20 cigarette smoke per day one year ) Postbronchodilator FEV1 ≥40 ≤ 80 % predict normal value Postbronchodilator FEV1/FVC &lt; 0,7 Reversibility airway obstruction accord reversibility test perform visit 2 , define increase FEV1 ≥10 % relative baseline inhalation total 400 μg salbutamol 1 mg terbutaline sulphate Chest radiography ( old 12 month Visit 2 ) show pathological change would make patient unsuitable inclusion judge Investigator Able read write use electronic device ( eDiary electronic spirometry ) Ability complete eDiary correctly . Baseline diary data record least 8 ( 8 ) last 10 day runin period accept patient randomize treatment ( Randomisation Criteria Visit 3 ) . Provision inform consent genetic sampling analysis . If patient decline participate pharmacogenetic research , consequence loss benefit patient . The patient exclude aspect study describe Clinical Study Protocol ( CSP ) , long consent ( Inclusion criterion patient take part pharmacogenetic research ) Significant disease disorder ( eg , cardiovascular , pulmonary COPD , gastrointestinal , liver , renal , neurological , musculoskeletal , endocrine , metabolic , malignant , psychiatric , major physical impairment ) , opinion investigator , may either put patient risk participation study , influence result study , patient 's ability participate study Any clinically relevant abnormal finding clinical chemistry , haematology , urinalysis , physical examination , pulse , blood pressure ECG Visit 2 , , opinion investigator , may put patient risk his/her participation study Requirement long term oxygen therapy An exacerbation COPD , define use oral parenteral glucocorticosteroids oral/parenteral antibiotic hospitalisation relate COPD within 6 week Visit 2 Participation schedule intensive COPD rehabilitation program Known suspect hypersensitivity study therapy excipients study drug History current alcohol drug abuse condition associate poor compliance judge investigator Plasma donation within one month screen blood donation/blood loss &gt; 500 mL 3 month prior screen . Participation clinical study investigational drug new formulation market drug 3 month prior Visit 2 Planned inpatient surgery hospitalisation study Previous randomisation treatment present study Involvement planning conduct study ( applies AstraZeneca staff staff study site ) Previous allogeneic bone marrow transplant ( Exclusion criterion patient take part pharmacogenetic research ) Nonleukocyte deplete whole blood transfusion within 120 day date genetic sample collection ( Exclusion criterion patient take part pharmacogenetic research )</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>COPD , FEV1 , AZD5423</keyword>
</DOC>